Similar Items: Alzheimer's disease drug development pipeline: 2026
- Meeting report for the Second International Conference on Unconventional Animal Models of Alzheimer's Disease and Aging (UAMAA 2026)
- Vascular cognitive impairment and dementia drug‐development pipeline 2025
- Deep contrastive learning framework identifies cell‐type‐specific drug targets in Alzheimer's disease
- Polypharmacy is associated with lower progression from MCI to Alzheimer's disease, with sex‐specific patterns across drug classes
- Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease
- Interchangeability of CSF and PET to identify Alzheimer's disease pathology